ADPD 2025 Presentation
2025 ADPD:
ALTITUDE-AD: Use of a pTau217 Assay as a Marker of Amyloid Burden for Screening Participants in an Ongoing Phase 2 Study of Sabirnetug in Early Alzheimer’s Disease

2025 ADPD:
ALTITUDE-AD: Use of a pTau217 Assay as a Marker of Amyloid Burden for Screening Participants in an Ongoing Phase 2 Study of Sabirnetug in Early Alzheimer’s Disease